PLSE

NEUTRALEarnings

Pulse Biosciences, Inc

2026-10-29

Price

$55.48

+5.32%

This is the 2026-10-29 snapshot — the signals and analysis for PLSE as of this single trading day.

View full PLSE research hub →

Score3.8Watchlist

Signals4/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

The bullish setup in PLSE is a textbook example of High-Conviction Price Discovery heading into its Q3 earnings on November 5. The stock's 25.0% monthly gain and PERFECT_STACK signal align perfectly with the current RISK_ON macro regime, as falling volatility and tight credit spreads encourage capital flows into high-beta med-tech growth stories. Supported by recent clinical enrollment milestones for its nano-PFA technology and an upcoming presentation at the Stifel Healthcare Conference, institutional buyers appear to be aggressively front-running these fundamental catalysts.

Fired Signals

SURGEGOLDEN CROSSMARKET LEADERPERFECT STACKEXTENSION

Key Takeaways

Actionable Thesis: Ride the pre-earnings momentum as PLSE exhibits High-Conviction Price Discovery, supported by top-tier technical signals (SURGE, MARKET_LEADER) and a risk-on macro backdrop.
Key Risk: With an annualized realized volatility of 87.3%, the stock is priced for perfection; any earnings disappointment or clinical delay could trigger severe multiple compression.
What to Watch: Monitor the Q3 earnings call on November 5 for updates on the NANOPULSE-AF IDE study, while using $43.32 as a strict trailing risk-management level.

← Back to 2026-10-29 View Full PLSE History →Yahoo Finance &nearr;